Substituted pyrazoles as novel sEH antagonist: investigation of key binding interactions within the catalytic domain.
Lo, H.Y., Man, C.C., Fleck, R.W., Farrow, N.A., Ingraham, R.H., Kukulka, A., Proudfoot, J.R., Betageri, R., Kirrane, T., Patel, U., Sharma, R., Hoermann, M.A., Kabcenell, A., Lombaert, S.D.(2010) Bioorg Med Chem Lett 20: 6379-6383
- PubMed: 20934334 
- DOI: https://doi.org/10.1016/j.bmcl.2010.09.095
- Primary Citation of Related Structures:  
3OTQ - PubMed Abstract: 
A novel series of pyrazole sEH inhibitors is reported. Lead optimization efforts to replace the aniline core are also described. In particular, 2-pyridine, 3-pyridine and pyridazine analogs are potent sEH inhibitors with favorable CYP3A4 inhibitory and microsomal stability profiles.
Organizational Affiliation: 
Boehringer Ingelheim Pharmaceuticals Inc., Biomolecular Screening, 900 Ridgebury Rd., PO Box 368, Ridgefield, CT 06877, USA. ho-yin.lo@boehringer-ingelheim.com